Severe acute respiratory syndrome coronavirus 2

Violet Defense Receiving Accreditation From American Institute of Architects

Retrieved on: 
Thursday, December 22, 2022
School, Coronavirus, Norovirus, AIA, Automation, Clostridioides difficile infection, Certification, American Institute, COVID-19, Disinfectant, MRSA, Escherichia coli, Accreditation, Severe acute respiratory syndrome coronavirus 2, Health, Atmosphere, UV, S. aureus, HVAC, Salmonella, Interior design, Sewage

With accreditation from the American Institute of Architects (AIA) in 2023, Violet Defense will create courses to educate architects on how they can incorporate UV disinfection technology into their core designs for sustainable buildings.

Key Points: 
  • With accreditation from the American Institute of Architects (AIA) in 2023, Violet Defense will create courses to educate architects on how they can incorporate UV disinfection technology into their core designs for sustainable buildings.
  • However, architects have had little guidance on how to include the technology during the design stage and face a significant hurdle.
  • "With AIA certification, we will create courses that will help architects incorporate UV disinfection technology into their designs right from the start."
  • Violet Defense technology already is in wide use nationwide, including hotels, convention centers, colleges and schools, and amateur and professional sports training facilities.

Altamira Therapeutics Provides Year-End 2022 Business Update

Retrieved on: 
Monday, December 19, 2022
Nasal spray, Infection, RNA interference, Randomized controlled trial, Therapy, Allergic rhinitis, NASAR, COVID-19, Interim, Lead, Viral load, R, Sale, SAR, Patient, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, US Foods, Safety, Nose, OTC, FDA, Allergy, RNA, Procurement, Medical device, Bank, Pharmaceutical industry, Vaccine, Database

Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023

Key Points: 
  • Database about to be locked in acute COVID-19 trial with Bentrio; top-line data expected by early January 2023
    HAMILTON, BERMUDA / December 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and key business developments.
  • The process for the sale of the other legacy assets – inner ear therapeutics – to a European family office (the “Buyer”) is still ongoing.
  • Dr. Pañeda joined the Company in April 2022 as Chief Development Officer for the RNA business.
  • “We are making solid progress with our transformation into an RNA delivery technology company,” stated Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO.

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

Retrieved on: 
Monday, December 19, 2022
Eli Lilly and Company, Neutralizing antibody, COVID-19, Policy, Severe acute respiratory syndrome coronavirus 2, FDA, EMA, Vaccine, Pharmaceutical industry

WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022.

Key Points: 
  • WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022.
  • Invivyd's chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants.
  • The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to support the expedited availability of novel monoclonal antibody therapies including those based on development stage products that have reported positive safety and efficacy data in clinical trials.
  • The industry presentation highlighted the significant unmet medical need for therapeutic options to prevent and treat COVID-19 along with scientifically sound, data driven policy change recommendations to shorten development timelines and keep pace with the rapid evolution of variants.

Worldwide Nasopharyngeal Cancer Industry to 2028 - North America is the Fastest Growing Region - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Pharmaceutical, Health, Oncology, EBRT, Hearing loss, Bone, Adenocarcinoma, MRI, Headache, IARC, Megasphaera, Woman, Tobacco, Severe acute respiratory syndrome coronavirus 2, MEA, American Institute, Initial, Squamous cell carcinoma, COVID-19, Organic, Pharynx, News, Immunotherapy, Brachytherapy, Research, Nasopharyngeal carcinoma, Growth, Patient, CT, Chemoradiotherapy, Weight loss, PET, Fatigue, Blurred, Hypoesthesia, Neck, Prevalence, Diagnosis, NPC, Cell, Dietary supplement, Pharmaceutical industry, Medical imaging, Marketing, Cancer

The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.

Key Points: 
  • The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.
  • According to the American Institute for Cancer Research estimates, Nasopharyngeal cancer is the 23rd most common cancer worldwide, and it is the 18th most commonly occurring cancer in men and the 22nd most commonly occurring cancer in women.
  • Thus, the high prevalence rate of nasopharyngeal cancer will increase the demands for effective drugs and therapies that will further lead to market growth.
  • The global nasopharyngeal cancer market is segmented based on cancer type, diagnosis method, and therapy.

Induced Pluripotent Stem Cells Production Global Market Report 2022: Absence of Ethical Issues, Personalized Treatment Options and Flexibility Drive Adoption - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Health, Stem Cells, Severe acute respiratory syndrome coronavirus 2, Blastomere, Degenerative disease, Cell culture, Stroke, Regenerative medicine, SARS, International Diabetes Federation, Heart, Biotechnology, Drug discovery, Therapy, Potency (pharmacology), IDF, Research, Drug development, Destiny, ESC, COVID-19, USD, Growth, Patient, Embryonic stem cell, B cell, Process, Conditional sentence, Business analysis, Chapter Five, Diabetes, Marketspace, Prevalence, Cell, Renewable energy, Pharmaceutical industry, Fine chemical, Workflow

The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030.

Key Points: 
  • The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030.
  • The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market.
  • Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth.
  • The key factors driving the revenue growth are the developed healthcare infrastructure, the prevalence of chronic diseases, the presence of strategic business models and funds by supportive government
    Chapter 4 Induced Pluripotent Stem Cells (Ipscs) Production Market: Process Business Analysis
    Chapter 5 Induced Pluripotent Stem Cells (Ipscs) Production Market: Workflow Business Analysis
    Chapter 6 Induced Pluripotent Stem Cells (Ipscs) Production Market: Product Business Analysis
    Chapter 7 Induced Pluripotent Stem Cells (Ipscs) Production Market: Application Business Analysis
    Chapter 8 Induced Pluripotent Stem Cells (Ipscs) Production Market: End-User Business Analysis
    Chapter 9 Induced Pluripotent Stem Cells (Ipscs) Production Market: Regional Business Analysis

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, Infection, COPD, Upper respiratory tract infection, Pharmacokinetics, RSV, Urinary tract infection, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PK, COVID-19, Risk, Human, Animal, Medication, Ferret, Patient, Severe acute respiratory syndrome coronavirus 2, Chronic obstructive pulmonary disease, Safety, Degenerative disease, FDA, Webcast, HBV, Conference, Asthma, Virology, Fast Track, Heart, Pharmaceutical industry, Vaccine, SPRINT

In RSV, we continue to expect top-line data from the Phase 1 study of EDP-323, our L-protein inhibitor, in the first half of 2023.

Key Points: 
  • In RSV, we continue to expect top-line data from the Phase 1 study of EDP-323, our L-protein inhibitor, in the first half of 2023.
  • Enanta expects to report data from this Phase 2 study in the first half of 2023.
  • Enanta also today announced a new research program focused on the discovery and development of inhibitors of the SARS-CoV-2 PLpro for the oral treatment of COVID-19.
  • A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines

Retrieved on: 
Thursday, January 5, 2023
Veterinary, Research, Infectious Diseases, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, LNP Media Group, BioRxiv, RNA transfection, Cornell University College of Veterinary Medicine, Applied Biosystems, DNA, Polymerase chain reaction, Dog, CDMO, CAR, Severe acute respiratory syndrome coronavirus 2, Veterinary medicine, Safety, Therapy, Applied DNA Sciences, Manuscript, Vaccine, PCR, LNP

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .
  • An initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022.
  • The study demonstrated safety and immunogenicity of a linearDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines.
  • Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort, which induced robust neutralizing antibody titers and cellular immune responses.

XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

Retrieved on: 
Thursday, January 5, 2023
Science, Biotechnology, Research, General Health, Health, COVID-19, Infectious Diseases, Other Health, Immunodeficiency, IC50, Risk, Disease, Patient, Severe acute respiratory syndrome coronavirus 2, Safety, Physician, Omicron, Antibody, WHO, COVID, Pharmaceutical industry

Several neutralization assays carried out by XENOTHERA have supplemented data already published ( Vanhove et al.

Key Points: 
  • Several neutralization assays carried out by XENOTHERA have supplemented data already published ( Vanhove et al.
  • XAV-19 exhibits a strong neutralization activity against all omicron variants, including BQ.1.1, the main variant of SARS-CoV-2 in circulation to date.
  • In the meantime, all monoclonal antibodies today marketed lose their activity against this variant.
  • The neutralizing concentration of XAV-19 (IC50) is identical to that measured for all other variants of SARS-CoV-2.

UVCeed to Showcase “Tripledemic” Protection at Eureka Park at CES 2023

Retrieved on: 
Wednesday, January 4, 2023
Technology, Biotechnology, Mobile, Wireless, Men, Health, Family, Consumer, Other Technology, Medical Devices, Infectious Diseases, Health Technology, Hardware, Women, Consumer Electronics, Bacteria, RSV, CES, Smartphone, IOS, COVID-19, Virus, Multimedia, Travel, LED, Android, UVC, Safety, Severe acute respiratory syndrome coronavirus 2, Vaccine, Video game console, Mobile phone

UVCeed today announced it will be demonstrating its flagship product, the world’s smartest mobile UV light sanitizer, at CES Eureka Park.

Key Points: 
  • UVCeed today announced it will be demonstrating its flagship product, the world’s smartest mobile UV light sanitizer, at CES Eureka Park.
  • Eureka Park at CES 2023 takes place January 5-8, 2023 in Las Vegas, Nevada.
  • View the full release here: https://www.businesswire.com/news/home/20230104005324/en/
    UVCeed is the first personal AI-powered mobile UVC disinfectant platform for work, home, school, or travel.
  • “Our UVCeed device has proven effective in preventing exposure to these viruses and keeping individuals and families safe.

Seoul Viosys: Through Air Purifier and Air Sterilizer Filters, Bacterial Growth and Leakage Occur

Retrieved on: 
Thursday, December 29, 2022
Semiconductor, Health, Medical Devices, Infectious Diseases, Technology, COVID-19, Hardware, Infection, KOSDAQ, Survival, Prof Bioresearch, Research, Federal Food, Drug, and Cosmetic Act, Staphylococcus epidermidis, Virus, Multimedia, Cosmetics, Donaldson Company, Diarrhea, Vomiting, HEPA, Genetically modified bacteria, Pain scale, Degenerative disease, Filter, Atmosphere, UV, Bacillus atrophaeus, COVID-19, KRW, Severe acute respiratory syndrome coronavirus 2, Sterilization, SOHO, Vaccine, Wine

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market.

Key Points: 
  • Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market.
  • The test confirms that bacterial growth and its leakage occur through the filters.
  • The Company announced filters in air purifiers and air sterilizers can cause viral infection and virus spread.
  • Air purifiers sold in the market were randomly selected and the filter contamination level was checked.